View All Documents & Correspondence
Human Cd30 Ligand Antigen Binding Proteins
Abstract: HUMAN CD30 LIGAND ANTIGEN BINDING PROTEINS Provided are compositions and methods relating to human CD30L antigen binding proteins. Compositions described herein include: human CD30L antigen binding proteins, polynucleotides encoding human CD30L antigen binding proteins, vectors comprising these polynucleotides, host cells, and pharmaceutical compositions. Methods of making and using each of these compositions are also provided.
Notices, Deadlines & Correspondence
Patent Information
Applicants
NOVO NORDISK A/S
AMGEN INC.
Inventors
1. ANDERSEN, Mette Dahl
2. DANTZLER, Jeff
3. ARMITAGE, Richard J.
4. CLARK, Rutilio
Claims
1. An isolated antigen binding protein that binds CD30L, wherein the antigen binding protein binds a C-terminal region of CD30L defined by AA 201-234.
2. An isolated antigen binding protein of claim 1, wherein the antigen binding protein binds a further region of CD30L defined by AA 75-95.
3. An isolated antigen binding protein of claim 1, wherein said antigen binding protein is an antibody.
4. An isolated antigen binding protein of claim 3, wherein said antigen binding protein is of the IgG1-, IgG2- IgG3- or IgG4-type.
5. A pharmaceutical composition comprising at least one antigen binding protein of claim 1 and pharmaceutically acceptable excipient.
7. An isolated nucleic acid molecule encoding an antigen binding protein of claim 1.
8. A host cell comprising the nucleic acid molecule of claim 7.
9. A method for treating or preventing a condition associated with CD30L in a patient, comprising administering to a patient in need thereof an effective amount of an antibody that binds CD30L, comprising: a) CDRH1, CDRH2, and CDRH3 identified by SEQ ID Nos: 14, 19, 25, and CDRL1, CDRL2 and CDRL3 identified by SEQ ID NO: 1, 7 and 11, b) CDRH1, CDRH2 and CDRH3 identified by SEQ ID Nos:15, 21, 26 and CDRL1, CDRL2 and CDRL3 identified by SEQ ID NO: 2, 8 and 12, c) CDRH1, CDRH2 and CDRH3 identified by SEQ ID Nos:15, 21, 26 and CDRL1, CDRL2 and CDRL3 identified by SEQ ID NO: 3, 8 and 12, d) CDRH1, CDRH2 and CDRH3 identified by SEQ ID Nos:16, 22, 27 and CDRL1, CDRL2 and CDRL3 identified by SEQ ID NO: 4, 9 and 12, e) CDRH1, CDRH2 and CDRH3 identified by SEQ ID Nos:17, 23, 28 and CDRL1, CDRL2 and CDRL3 identified by SEQ ID NO: 5, 8 and 13 or f) CDRH1, CDRH2 and CDRH3 identified by SEQ ID Nos:18, 24, 29 and CDRL1, CDRL2 and CDRL3 identified by SEQ ID NO: 6, 10 and 12.
10. A method of reducing CD30L activity in a patient comprising administering an effective amount of an antibody comprising a) CDRH1, CDRH2, and CDRH3 identified by SEQ ID Nos: 14, 19, 25, and CDRL1, CDRL2 and CDRL3 identified by SEQ ID NO: 1, 7 and 11, b) CDRH1, CDRH2 and CDRH3 identified by SEQ ID Nos:15, 21, 26 and CDRL1, CDRL2 and CDRL3 identified by SEQ ID NO: 2, 8 and 12, c) CDRH1, CDRH2 and CDRH3 identified by SEQ ID Nos:15, 21, 26 and CDRL1, CDRL2 and CDRL3 identified by SEQ ID NO: 3, 8 and 12, d) CDRH1, CDRH2 and CDRH3 identified by SEQ ID Nos:16, 22, 27 and CDRL1, CDRL2 and CDRL3 identified by SEQ ID NO: 4, 9 and 12, e) CDRH1, CDRH2 and CDRH3 identified by SEQ ID Nos:17, 23, 28 and CDRL1, CDRL2 and CDRL3 identified by SEQ ID NO: 5, 8 and 13 or f) CDRH1, CDRH2 and CDRH3 identified by SEQ ID Nos:18, 24, 29 and CDRL1, CDRL2 and CDRL3 identified by SEQ ID NO: 6, 10 and 12.
Specification
Description:AS ATTACHED , Claims:AS ATTACHED
I/We Claim:
1. An isolated antigen binding protein that binds CD30L, wherein the antigen binding
protein binds a C-terminal region of CD30L defined by AA 201-234.
2. An isolated antigen binding protein of claim 1, wherein the antigen binding protein binds
a further region of CD30L defined by AA 75-95.
3. An isolated antigen binding protein of claim 1, wherein said antigen binding protein is
an antibody.
4. An isolated antigen binding protein of claim 3, wherein said antigen binding protein is
of the IgG1-, IgG2- IgG3- or IgG4-type.
5. A pharmaceutical composition comprising at least one antigen binding protein of claim
1 and pharmaceutically acceptable excipient.
7. An isolated nucleic acid molecule encoding an antigen binding protein of claim 1.
8. A host cell comprising the nucleic acid molecule of claim 7.
9. A method for treating or preventing a condition associated with CD30L in a patient,
comprising administering to a patient in need thereof an effective amount of an antibody
that binds CD30L, comprising:
a) CDRH1, CDRH2, and CDRH3 identified by SEQ ID Nos: 14, 19, 25, and CDRL1,
CDRL2 and CDRL3 identified by SEQ ID NO: 1, 7 and 11,
b) CDRH1, CDRH2 and CDRH3 identified by SEQ ID Nos:15, 21, 26 and CDRL1,
CDRL2 and CDRL3 identified by SEQ ID NO: 2, 8 and 12,
c) CDRH1, CDRH2 and CDRH3 identified by SEQ ID Nos:15, 21, 26 and CDRL1,
CDRL2 and CDRL3 identified by SEQ ID NO: 3, 8 and 12,
d) CDRH1, CDRH2 and CDRH3 identified by SEQ ID Nos:16, 22, 27 and CDRL1,
CDRL2 and CDRL3 identified by SEQ ID NO: 4, 9 and 12,
e) CDRH1, CDRH2 and CDRH3 identified by SEQ ID Nos:17, 23, 28 and CDRL1,
CDRL2 and CDRL3 identified by SEQ ID NO: 5, 8 and 13 or
f) CDRH1, CDRH2 and CDRH3 identified by SEQ ID Nos:18, 24, 29 and CDRL1,
CDRL2 and CDRL3 identified by SEQ ID NO: 6, 10 and 12.
10. A method of reducing CD30L activity in a patient comprising administering an effective
amount of an antibody comprising
a) CDRH1, CDRH2, and CDRH3 identified by SEQ ID Nos: 14, 19, 25, and CDRL1,
CDRL2 and CDRL3 identified by SEQ ID NO: 1, 7 and 11,
b) CDRH1, CDRH2 and CDRH3 identified by SEQ ID Nos:15, 21, 26 and CDRL1,
CDRL2 and CDRL3 identified by SEQ ID NO: 2, 8 and 12,
c) CDRH1, CDRH2 and CDRH3 identified by SEQ ID Nos:15, 21, 26 and CDRL1,
CDRL2 and CDRL3 identified by SEQ ID NO: 3, 8 and 12,
d) CDRH1, CDRH2 and CDRH3 identified by SEQ ID Nos:16, 22, 27 and CDRL1,
CDRL2 and CDRL3 identified by SEQ ID NO: 4, 9 and 12,
e) CDRH1, CDRH2 and CDRH3 identified by SEQ ID Nos:17, 23, 28 and CDRL1,
CDRL2 and CDRL3 identified by SEQ ID NO: 5, 8 and 13 or
f) CDRH1, CDRH2 and CDRH3 identified by SEQ ID Nos:18, 24, 29 and CDRL1,
CDRL2 and CDRL3 identified by SEQ ID NO: 6, 10 and 12.
Documents
Application Documents
| # | Name | Date |
|---|---|---|
| 1 | 202448025547-STATEMENT OF UNDERTAKING (FORM 3) [28-03-2024(online)].pdf | 2024-03-28 |
| 2 | 202448025547-Sequence Listing in txt [28-03-2024(online)].txt | 2024-03-28 |
| 3 | 202448025547-Sequence Listing in PDF [28-03-2024(online)].pdf | 2024-03-28 |
| 4 | 202448025547-REQUEST FOR EXAMINATION (FORM-18) [28-03-2024(online)].pdf | 2024-03-28 |
| 5 | 202448025547-POWER OF AUTHORITY [28-03-2024(online)].pdf | 2024-03-28 |
| 6 | 202448025547-FORM 18 [28-03-2024(online)].pdf | 2024-03-28 |
| 7 | 202448025547-FORM 1 [28-03-2024(online)].pdf | 2024-03-28 |
| 8 | 202448025547-DRAWINGS [28-03-2024(online)].pdf | 2024-03-28 |
| 9 | 202448025547-DECLARATION OF INVENTORSHIP (FORM 5) [28-03-2024(online)].pdf | 2024-03-28 |
| 10 | 202448025547-COMPLETE SPECIFICATION [28-03-2024(online)].pdf | 2024-03-28 |
| 11 | 202448025547-FORM-26 [15-04-2024(online)].pdf | 2024-04-15 |
| 12 | 202448025547-FORM 3 [03-09-2024(online)].pdf | 2024-09-03 |